دورية أكاديمية
أعرض في EDS

Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study.

التفاصيل البيبلوغرافية
العنوان: Repurposing of a Thromboxane Receptor Inhibitor Based on a Novel Role in Metastasis Identified by Phenome-Wide Association Study.
المؤلفون: Werfel TA; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Department of Chemical Engineering, University of Mississippi, Oxford, Mississippi., Hicks DJ; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee., Rahman B; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee., Bendeman WE; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee., Duvernay MT; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee., Maeng JG; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee., Hamm H; Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee., Lavieri RR; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee., Joly MM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee., Pulley JM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee., Elion DL; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee., Brantley-Sieders DM; Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Cook RS; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, Tennessee. rebecca.cook@vanderbilt.edu.; Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.; Breast Cancer Research Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, Tennessee.
المصدر: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Dec; Vol. 19 (12), pp. 2454-2464. Date of Electronic Publication: 2020 Oct 08.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Association for Cancer Research, Inc., c2001-
مواضيع طبية MeSH: Drug Repositioning*, Antineoplastic Agents/*pharmacology , Genome-Wide Association Study/*methods , Receptors, Thromboxane/*antagonists & inhibitors , Receptors, Thromboxane/*genetics, Cell Line, Tumor ; Drug Screening Assays, Antitumor/methods ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Neoplasm Metastasis ; Phenotype ; Polymorphism, Single Nucleotide ; Receptors, Thromboxane/metabolism
مستخلص: Although new drug discoveries are revolutionizing cancer treatments, repurposing existing drugs would accelerate the timeline and lower the cost for bringing treatments to cancer patients. Our goal was to repurpose CPI211, a potent and selective antagonist of the thromboxane A 2 -prostanoid receptor (TPr), a G-protein-coupled receptor that regulates coagulation, blood pressure, and cardiovascular homeostasis. To identify potential new clinical indications for CPI211, we performed a phenome-wide association study (PheWAS) of the gene encoding TPr, TBXA2R , using robust deidentified health records and matched genomic data from more than 29,000 patients. Specifically, PheWAS was used to identify clinical manifestations correlating with a TBXA2R single-nucleotide polymorphism (rs200445019), which generates a T399A substitution within TPr that enhances TPr signaling. Previous studies have correlated 200445019 with chronic venous hypertension, which was recapitulated by this PheWAS analysis. Unexpectedly, PheWAS uncovered an rs200445019 correlation with cancer metastasis across several cancer types. When tested in several mouse models of metastasis, TPr inhibition using CPI211 potently blocked spontaneous metastasis from primary tumors, without affecting tumor cell proliferation, motility, or tumor growth. Further, metastasis following intravenous tumor cell delivery was blocked in mice treated with CPI211. Interestingly, TPr signaling in vascular endothelial cells induced VE-cadherin internalization, diminished endothelial barrier function, and enhanced transendothelial migration by tumor cells, phenotypes that were decreased by CPI211. These studies provide evidence that TPr signaling promotes cancer metastasis, supporting the study of TPr inhibitors as antimetastatic agents and highlighting the use of PheWAS as an approach to accelerate drug repurposing.
(©2020 American Association for Cancer Research.)
References: Denny JC, Ritchie MD, Basford MA, Pulley JM, Bastarache L, Brown-Gentry K, et al. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene-disease associations. Bioinformatics. 2010;26:1205–10.
Pulley JM, Jerome RN, Ogletree ML, Bernard GR, Lavieri RR, Zaleski NM, et al. Motivation for launching a cancer metastasis inhibition (CMI) program. Target Oncol. 2018;13:61–8.
Pulley JM, Shirey-Rice JK, Lavieri RR, Jerome RN, Zaleski NM, Aronoff DM, et al. Accelerating precision drug development and drug repurposing by leveraging human genetics. Assay Drug Dev Technol. 2017;15:113–9.
Schumacher WA, Steinbacher TE, Youssef S, Ogletree ML. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins. 1992;44:389–97.
Jones RL, Giembycz MA, Woodward DF. Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol. 2009;158:104–45.
Ogletree ML, Harris DN, Schumacher WA, Webb ML, Misra RN. Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther. 1993;264:570–8.
95th annual meeting of the American Society for Clinical Pharmacology and Therapeutics. New Orleans, Louisiana, March 30-April 1, 1994. Abstracts. Clin Pharmacol Ther. 1994;55:123–218.
Fontana P, Zufferey A, Daali Y, Reny JL. Antiplatelet therapy: targeting the TxA2 pathway. J Cardiovasc Transl Res. 2014;7:29–38.
Nakahata N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol Ther. 2008;118:18–35.
Jerome RN, Pulley JM, Roden DM, Shirey-Rice JK, Bastarache LA, G RB, et al. Using human ‘experiments of nature’ to predict drug safety issues: an example with PCSK9 inhibitors. Drug Saf. 2018;41:303–11.
Mundell SJ, Mumford A. TBXA2R gene variants associated with bleeding. Platelets. 2018;29:739–42.
Yi X, Lin J, Zhou Q, Huang R, Chai Z. The TXA2R rs1131882, P2Y1 rs1371097 and GPIIIa rs2317676 three-loci interactions may increase the risk of carotid stenosis in patients with ischemic stroke. BMC Neurol. 2019;19:44.
Milanowski L, Pordzik J, Janicki PK, Kaplon-Cieslicka A, Rosiak M, Peller M, et al. New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study. Acta Diabetol. 2017;54:343–51.
Bauer J, Ripperger A, Frantz S, Ergun S, Schwedhelm E, Benndorf RA. Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation. Br J Pharmacol. 2014;171:3115–31.
Takeuchi K, Mashimo Y, Shimojo N, Arima T, Inoue Y, Morita Y, et al. Functional variants in the thromboxane A2 receptor gene are associated with lung function in childhood-onset asthma. Clin Exp Allergy. 2013;43:413–24.
Sasaki M, Sukegawa J, Miyosawa K, Yanagisawa T, Ohkubo S, Nakahata N. Low expression of cell-surface thromboxane A2 receptor beta-isoform through the negative regulation of its membrane traffic by proteasomes. Prostaglandins Other Lipid Mediat. 2007;83:237–49.
Hamelin E, Theriault C, Laroche G, Parent JL. The intracellular trafficking of the G protein-coupled receptor TPbeta depends on a direct interaction with Rab11. J Biol Chem. 2005;280:36195–205.
Laroche G, Rochdi MD, Laporte SA, Parent JL. Involvement of actin in agonist-induced endocytosis of the G protein-coupled receptor for thromboxane A2: overcoming of actin disruption by arrestin-3 but not arrestin-2. J Biol Chem. 2005;280:23215–24.
Parent JL, Labrecque P, Orsini MJ, Benovic JL. Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced cooh terminus in agonist-promoted receptor internalization. J Biol Chem. 1999;274:8941–8.
Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84:362–9.
Pulley J, Clayton E, Bernard GR, Roden DM, Masys DR. Principles of human subjects protections applied in an opt-out, de-identified biobank. Clin Transl Sci. 2010;3:42–8.
Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics. 2014;30:2375–6.
Brantley-Sieders DM, Fang WB, Hwang Y, Hicks D, Chen J. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res. 2006;66:10315–24.
Duvernay M, Young S, Gailani D, Schoenecker J, Hamm HE. Protease-activated receptor (PAR) 1 and PAR4 differentially regulate factor V expression from human platelets. Mol Pharmacol. 2013;83:781–92.
Elion DL, Jacobson ME, Hicks DJ, Rahman B, Sanchez V, Gonzales-Ericsson PI, et al. Therapeutically active RIG-I agonist induces immunogenic tumor cell killing in breast cancers. Cancer Res. 2018;78:6183–95.
Qu S, Rinehart C, Wu HH, Wang SE, Carter B, Xin H, et al. Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy. Genesis. 2006;44:477–86.
Youngblood V, Wang S, Song W, Walter D, Hwang Y, Chen J, et al. Elevated Slit2 activity impairs VEGF-induced angiogenesis and tumor neovascularization in EphA2-deficient endothelium. Mol Cancer Res. 2015;13:524–37.
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–52.
Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8:e82241.
Ashton AW, Ware JA. Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res. 2004;95:372–9.
De Bock K, Cauwenberghs S, Carmeliet P. Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications. Curr Opin Genet Dev. 2011;21:73–9.
Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE, et al. Endothelial Notch1 activity facilitates metastasis. Cancer Cell. 2017;31:355–67.
Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211.
Zhao Z, Hu J, Gao X, Liang H, Yu H, Liu S, et al. Hyperglycemia via activation of thromboxane A2 receptor impairs the integrity and function of blood-brain barrier in microvascular endothelial cells. Oncotarget. 2017;8:30030–8.
Xie X, Sun W, Wang J, Li X, Liu X, Liu N. Activation of thromboxane A2 receptors mediates endothelial dysfunction in diabetic mice. Clin Exp Hypertens. 2017;39:312–8.
Dejana E, Orsenigo F, Lampugnani MG. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci. 2008;121:2115–22.
Cai J, Jiang WG, Mansel RE. Phosphorylation and disorganization of vascular-endothelial cadherin in interaction between breast cancer and vascular endothelial cells. Int J Mol Med. 1999;4:191–5.
Mazzone M, Dettori D, de Oliveira RL, Loges S, Schmidt T, Jonckx B, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 2009;136:839–51.
Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 2010;70:5649–69.
Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–37.
Lucotti S, Cerutti C, Soyer M, Gil-Bernabe AM, Gomes AL, Allen PD, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest. 2019;129:1845–62.
Matsui Y, Amano H, Ito Y, Eshima K, Suzuki T, Ogawa F, et al. Thromboxane A(2) receptor signaling facilitates tumor colonization through P-selectin-mediated interaction of tumor cells with platelets and endothelial cells. Cancer Sci. 2012;103:700–7.
Sawada J, Urakami T, Li F, Urakami A, Zhu W, Fukuda M, et al. Small GTPase R-Ras regulates integrity and functionality of tumor blood vessels. Cancer Cell. 2012;22:235–49.
معلومات مُعتمدة: S10 OD023475 United States OD NIH HHS; UL1 TR000445 United States TR NCATS NIH HHS; P50 CA098131 United States CA NCI NIH HHS
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Receptors, Thromboxane)
تواريخ الأحداث: Date Created: 20201009 Date Completed: 20210812 Latest Revision: 20220719
رمز التحديث: 20240628
DOI: 10.1158/1535-7163.MCT-19-1106
PMID: 33033174
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-8514
DOI:10.1158/1535-7163.MCT-19-1106